Author:
Yang Tsung-Mu,Singla Nirmish,Chen Chung-Hsin,Hsieh Jer-Tsong,Yeh Hsin-Chih
Reference9 articles.
1. Genetic differences between bladder and upper urinary tract carcinoma: Implications for therapy;Sfakianos;Eur Urol Oncol,2021
2. A delay in radical nephroureterectomy can lead to upstaging;Waldert;BJU Int,2010
3. The surveillance, epidemiology, and end results program: A national resource;Hankey;Cancer Epidemiol Biomarkers Prev,1999
4. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial;Powles;Lancet Oncol,2021
5. LBA27 Phase II multicenter, randomized study to evaluate efficacy and safety of avelumab with gemcitabine/carboplatin (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy;Perez Valderrama;Ann Oncol,2020